Skip to content
Jeffrey R. Andolina, M.D., M.S.

Jeffrey R. Andolina, M.D., M.S.

Pediatrics , Pediatric Brain and Spinal Cord Tumor , Cancer

5 out of 5 stars
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

About Me

Dr. Andolina is most interested in the treatment and comprehensive care for children with leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as the care for children with other cancers and blood diseases. ...
Dr. Andolina is most interested in the treatment and comprehensive care for children with leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as the care for children with other cancers and blood diseases.

Dr. Andolina is the Director of Pediatric Bone Marrow Transplantation and has experience in treating both Leukemias, as well as non-malignant conditions including aplastic anemia and Immunodeficiencies. He has a particular interest in bone marrow transplant for patients with sickle cell anemia. In addition, Dr. Andolina has an interest in the adolescent and young adult population; he also cares for young adults undergoing bone marrow transplantation.

The University of Rochester is a member of multiple cooperative groups for pediatric cancer and pediatric bone marrow transplantation, including the Children's Oncology Group (COG), the Pediatric Blood and Marrow Tissue Consortium (PBMTC), and the Primary Immune Deficiency Treatment Consortium (PIDTC). Dr. Andolina is an investigator with each of these national groups and is the primary investigator for the PBMTC and PIDTC. He is on both the CML disease committee and also the cellular therapy committee of the COG. Together, we have over 75 clinical trials open and strive to have all front-line treatment studies open for our pediatric and young adult patients.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Certified Specialties

Pediatric Hematology-Oncology - American Board of Pediatrics

Faculty Appointments

Associate Professor - Department of Pediatrics, Hematology and Oncology (SMD)

Credentials

Education

MD | University of Virginia School of Medicine. 2004

Awards

Strong Friend Award - Presented by C.U.R.E. Childhood Cancer Association. 2024

Make-A-Wish Award on behalf of Golisano Children's Hospital. 2024

Make a Difference Award, presented by Adolescent and young adult group 13Thirty cancer connect. 2022

Faculty Teaching Award for Pediatrics. 2022

Faculty Teaching Award for Pediatrics. 2021

Faculty Teaching Award for Pediatrics, presented by medical student class of 2021. 2020 - 2020

Early Career Distinguished Service Award. 2017 - 2017

Faculty Teaching Award for Pediatrics, presented by medical student class of 2019. 2017 - 2018

Young Investigator Award, travel stipend. 2016 - 2016

ICare Bronze Star Award. 2015 - 2015

Faculty Teaching Award. 2015 - 2016

Ruth A. Lawrence Academic Faculty Service Award. 2015 - 2016

Faculty Teaching Award for Pediatrics presented by UR Medicine Medical Student Class of 2016. 2014 - 2015

Alpha Omega Alpha (AOA). 2013 - 2014

Faculty Teaching Award for Pediatrics. 2013 - 2014

Children's Oncology Group Primary Investigator (PI). 2012

A. Todd Davis Physician Award. 2007

Resident Teaching Award. 2007

Resident Teaching Award. 2005

Gold Humanism in Medicine Honor Society. 2004

Research

Dr. Andolina is interested in improving the outcome for children with cancer through offering enrollment on multi-institutional clinical trials through the Children's Oncology Group (COG) and Pediatric Blood and Marrow Tissue Consortium (PBMTC).

Dr. Andolina has a particular interest in Pedia...
Dr. Andolina is interested in improving the outcome for children with cancer through offering enrollment on multi-institutional clinical trials through the Children's Oncology Group (COG) and Pediatric Blood and Marrow Tissue Consortium (PBMTC).

Dr. Andolina has a particular interest in Pediatric Bone Marrow Transplantation; Leukemia; Lymphoma; Neuroblastoma; Hematology, Oncology; Pediatric Hematology Oncology; Pediatric Oncology; Pediatric Cancer.

Dr. Andolina's research interests including improving bone marrow transplantation for children and young adults. He and colleagues have developed a clinical trial using haploidentical donors for bone marrow transplant, for those patients without fully matched sibling or matched unrelated donors. Haploidentical donors are "half matches," and almost all patients will have an available haploidentical donor, as all biological parents and half of full siblings will fall into this category.

Other research interests include evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.

Dr. Andolina also performs laboratory research including the study of the gene expression profile of acute lymphoblastic leukemia cells, specifically evaluating gene expression changes which may confer survival advantages post-allogeneic hematopoietic stem cell transplantation.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Clinical Trials

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Lead Researcher: Jeffrey R Andolina

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or ...

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Lead Researcher: Jeffrey R Andolina

Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation (BMT) has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo th...

A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)

Lead Researcher: Jeffrey R Andolina

This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related vari...

Publications

Journal Articles

Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series.

Bowden A, Zambito J, El-Feghaly J, Andolina JR

Pediatric hematology and oncology.. 2024 September 41 (6):389-398. Epub 05/07/2024.

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.

Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LM, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA

Blood advances.. 2023 July 257 (14):3725-3734. Epub 1900 01 01.

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium.

Thakar MS, Logan BR, Puck JM, Dunn EA, Buckley RH, Cowan MJ, O'Reilly RJ, Kapoor N, Satter LF, Pai SY, Heimall J, Chandra S, Ebens CL, Chellapandian D, Williams O, Burroughs LM, Saldana BD, Rayes A, Madden LM, Chandrakasan S, Bednarski JJ, DeSantes KB, Cuvelier GDE, Teira P, Gillio AP, Eissa H, Knutsen AP, Goldman FD, Aquino VM, Shereck EB, Moore TB, Caywood EH, Lugt MTV, Rozmus J, Broglie L, Yu LC, Shah AJ, Andolina JR, Liu X, Parrott RE, Dara J, Prockop S, Martinez CA, Kapadia M, Jyonouchi SC, Sullivan KE, Bleesing JJ, Chaudhury S, Petrovic A, Keller MD, Quigg TC, Parikh S, Shenoy S, Seroogy C, Rubin T, Decaluwe H, Routes JM, Torgerson TR, Leiding JW, Pulsipher MA, Kohn DB, Griffith LM, Haddad E, Dvorak CC, Notarangelo LD

Lancet.. 2023 July 8402 (10396):129-140. Epub 06/20/2023.

Association of crystalloid fluid infusion with intravascular hemolysis and organ dysfunction in hematopoietic stem cell transplant patients.

Holloway MR, Fountaine T, Henrichs K, Feeney T, Andolina J, O'Dwyer K, Liesveld J, Blumberg N, Huselton E

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.. 2023 June 62 (3):103641. Epub 01/13/2023.

Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.

Parisi R, Patel RR, Rood G, Bowden A, Turco G, Korones DN, Andolina JR, Comito M, Barth M, Weintraub L

Pediatric blood & cancer.. 2023 March 70 (3):e30139. Epub 12/26/2022.

The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions.

Dvorak CC, Haddad E, Heimall J, Dunn E, Cowan MJ, Pai SY, Kapoor N, Satter LF, Buckley RH, O'Reilly RJ, Chandra S, Bednarski JJ, Williams O, Rayes A, Moore TB, Ebens CL, Davila Saldana BJ, Petrovic A, Chellapandian D, Cuvelier GDE, Vander Lugt MT, Caywood EH, Chandrakasan S, Eissa H, Goldman FD, Shereck E, Aquino VM, Desantes KB, Madden LM, Miller HK, Yu L, Broglie L, Gillio A, Shah AJ, Knutsen AP, Andolina JP, Joshi AY, Szabolcs P, Kapadia M, Martinez CA, Parrot RE, Sullivan KE, Prockop SE, Abraham RS, Thakar MS, Leiding JW, Kohn DB, Pulsipher MA, Griffith LM, Notarangelo LD, Puck JM

The Journal of allergy and clinical immunology.. 2023 February 151 (2):547-555.e5. Epub 11/28/2022.

Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent.

Fries C, Evans AG, Cheon H, Korones DN, Loughran TP, Andolina JR

Journal of pediatric hematology/oncology.. 2022 August 144 (6):e960-e963. Epub 12/29/2021.

Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML.

Smith SM, Zhang S, Sundaram V, Roth M, Andolina JR, Schapira L, Sakamoto KM, Kolb EA, Hijiya N, Chaudhury S

Pediatric hematology and oncology.. 2022 August 39 (5):453-467. Epub 12/17/2021.

Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network.

Avutu V, Monga V, Mittal N, Saha A, Andolina JR, Bell DE, Fair DB, Flerlage JE, Frediani JN, Heath JL, Kahn JM, Reichek JL, Super L, Terao MA, Freyer DR, Roth ME

JCO oncology practice.. 2022 March 18 (3):224-231. Epub 12/14/2021.

Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.

Andolina JR, Wang YC, Ji L, Freyer DR, Levine JE, Pulsipher MA, Gamis AS, Aplenc R, Roth ME, Harrison L, Cairo MS

Bone marrow transplantation.. 2022 March 57 (3):445-452. Epub 01/06/2022.

Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants.

Andolina JR, Fries C, Boulware R, Vargas A, Fraint E, Barth M, Abrusko S, Comito M, Monteleone P

Journal of pediatric hematology/oncology.. 2022 January 144 (1):e264-e267. Epub 1900 01 01.

Migratory Arthralgia in a 3-year-old Girl.

Fries C, Long AM, Marston BA, Andolina JR

Pediatrics in review. 2022 January 143 (1):41-44. Epub 1900 01 01.

Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.

Eastburg L, Russler-Germain DA, DiPersio JF, Fountaine T, Andolina JR, Abboud R, Huselton E

Leukemia & lymphoma.. 2022 January 63 (1):222-226. Epub 11/18/2021.

Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children.

Fries C, Girvin AR, Korones DN, Weintraub L, Fitzpatrick L, Andolina JR

Journal of pediatric hematology/oncology.. 2021 November 143 (8):e1223-e1227. Epub 1900 01 01.

Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva.

Kaplan FS, Teachey DT, Andolina JR, Siegel DM, Mancilla EE, Hsiao EC, Al Mukaddam M, Rocke DM, Pignolo RJ

Bone.. 2021 September 150 :116016. Epub 05/19/2021.

Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant.

Schenone D, Andolina JR, Rademacher B, Fountaine TJ, Edwards E, Nunez L, Qiu M, Sharma S, Mullen CA

Anticancer research.. 2021 June 41 (6):2781-2793. Epub 1900 01 01.

Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.

Dorsey MJ, Wright NAM, Chaimowitz NS, Dávila Saldaña BJ, Miller H, Keller MD, Thakar MS, Shah AJ, Abu-Arja R, Andolina J, Aquino V, Barnum JL, Bednarski JJ, Bhatia M, Bonilla FA, Butte MJ, Bunin NJ, Chandra S, Chaudhury S, Chen K, Chong H, Cuvelier GDE, Dalal J, DeFelice ML, DeSantes KB, Forbes LR, Gillio A, Goldman F, Joshi AY, Kapoor N, Knutsen AP, Kobrynski L, Lieberman JA, Leiding JW, Oshrine B, Patel KP, Prockop S, Quigg TC, Quinones R, Schultz KR, Seroogy C, Shyr D, Siegel S, Smith AR, Torgerson TR, Vander Lugt MT, Yu LC, Cowan MJ, Buckley RH, Dvorak CC, Griffith LM, Haddad E, Kohn DB, Logan B, Notarangelo LD, Pai SY, Puck J, Pulsipher MA, Heimall J

Journal of clinical immunology.. 2021 January 41 (1):38-50. Epub 10/02/2020.

Non-donor specific anti-human leukocyte antigen (HLA) antibodies are not associated with poor outcome in hematopoietic stem cell transplant recipients.

Andolina JR, Walia R, Oliva J, Baran A, Liesveld J, Becker MW, Busacco A, Coppage M.

Hum Immunol. 2020; S0198-8859(20): 30318-9.

StALKing Histiocytosis: ALK-positive histiocytosis identified through peripheral blood smear (in press)

Andolina JR.

Acta Haematol. 2020; .

Reexamining 1-Gene Deletion ?-Thalassemia: Is the Silent Carrier of Clinical Significance?

Andolina JR

Acta haematologica.. 2020 143 (5):407-409. Epub 11/27/2019.

Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.

Chan AY, Leiding JW, Liu X, Logan BR, Burroughs LM, Allenspach EJ, Skoda-Smith S, Uzel G, Notarangelo LD, Slatter M, Gennery AR, Smith AR, Pai SY, Jordan MB, Marsh RA, Cowan MJ, Dvorak CC, Craddock JA, Prockop SE, Chandrakasan S, Kapoor N, Buckley RH, Parikh S, Chellapandian D, Oshrine BR, Bednarski JJ, Cooper MA, Shenoy S, Davila Saldana BJ, Forbes LR, Martinez C, Haddad E, Shyr DC, Chen K, Sullivan KE, Heimall J, Wright N, Bhatia M, Cuvelier GDE, Goldman FD, Meyts I, Miller HK, Seidel MG, Vander Lugt MT, Bacchetta R, Weinacht KG, Andolina JR, Caywood E, Chong H, de la Morena MT, Aquino VM, Shereck E, Walter JE, Dorsey MJ, Seroogy CM, Griffith LM, Kohn DB, Puck JM, Pulsipher MA, Torgerson TR

Frontiers in immunology.. 2020 11 :239. Epub 02/21/2020.

Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group.

Athale U, Hijiya N, Patterson BC, Bergsagel J, Andolina JR, Bittencourt H, Schultz KR, Burke MJ, Redell MS, Kolb EA, Johnston DL

Pediatric blood & cancer.. 2019 September 66 (9):e27827. Epub 06/10/2019.

Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia.

Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2019 February 25 (2):321-327. Epub 09/26/2018.

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.

Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA

Blood.. 2018 September 27132 (13):1438-1451. Epub 07/11/2018.

Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children.

Andolina JR, Reinish AL, Akhtar R, Noronha S, Shand JC, Girvin A, Korones DN, Bruckner LB, Mullen CA, Curran KJ, Boulad F

Pediatric blood & cancer.. 2018 August 65 (8):e27218. Epub 05/03/2018.

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ

Bone.. 2018 April 109 :276-280. Epub 07/20/2017.

Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

Hammond WJ, Lalazar G, Saltsman JA, Farber BA, Danzer E, Sherpa TC, Banda CD, Andolina JR, Karimi S, Brennan CW, Torbenson MS, La Quaglia MP, Simon SM

Pediatric blood & cancer.. 2018 April 65 (4)Epub 12/29/2017.

Factors Associated With Noncompliance With Long-term Follow-up Care Among Pediatric Cancer Survivors.

Devine KA, Viola A, Capucilli P, Sahler OJ, Andolina JR

Journal of pediatric hematology/oncology.. 2017 April 39 (3):167-173. Epub 1900 01 01.

Ovarian carcinoma in a 14-year-old with classical salt-wasting congenital adrenal hyperplasia and bilateral adrenalectomy.

Pina C, Khattab A, Katzman P, Bruckner L, Andolina J, New M, Yau M

Journal of pediatric endocrinology & metabolism : JPEM.. 2015 May 28 (5-6):663-7. Epub 1900 01 01.

Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.

Mehta HM, Futami M, Glaubach T, Lee DW, Andolina JR, Yang Q, Whichard Z, Quinn M, Lu HF, Kao WM, Przychodzen B, Sarkar CA, Minella A, Maciejewski JP, Corey SJ

Leukemia.. 2014 May 28 (5):1041-51. Epub 10/30/2013.

Solid adrenal mass: not always what it seems.

Spaniolas K, Huang JL, Ruan DT, Akhtar R, Andolina JR, Moalem J

The American surgeon.. 2014 February 80 (2):E47-8. Epub 1900 01 01.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

Liesveld JL, Phillips GL, Becker M, Constine LS, Friedberg J, Andolina JR, Milner LA, Debolt J, Smudzin T, Hyrien O, Erickson-Miller CL, Johnson BM, Dawson KL, Chen Y

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2013 December 19 (12):1745-52. Epub 10/08/2013.

Shwachman-Diamond syndrome: diarrhea, no longer required?

Andolina JR, Morrison CB, Thompson AA, Chaudhury S, Mack AK, Proytcheva M, Corey SJ

Journal of pediatric hematology/oncology.. 2013 August 35 (6):486-9. Epub 1900 01 01.

Horner syndrome in a newly diagnosed patient with high risk precursor B-cell acute lymphoblastic leukemia.

Fountaine TJ, Miller B, Khalifa YM, Andolina JR

Pediatric blood & cancer.. 2012 August 59 (2):344. Epub 01/09/2012.

How I treat childhood CML.

Andolina JR, Neudorf SM, Corey SJ

Blood.. 2012 February 23119 (8):1821-30. Epub 12/30/2011.

Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease.

Andolina JR, Kletzel M, Tse WT, Jacobsohn DA, Duerst RE, Schneiderman J, Helenowski I, Rademaker A, Chaudhury S

Pediatric transplantation.. 2011 May 15 (3):334-43. Epub 02/24/2011.

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors

Andolina JR, Dilley K.

Journal Pediatric Hematology Oncology. 2010; 32(5): 411-5.

Are kinases factors in core binding factor leukemia?.

Andolina, J. R., & Corey, S. J.

Leukemia & lymphoma. 2009; 50(9): 1397-1398.

Books

Signs and Symptoms in Pediatrics (2023)

Chapter: Lymphadenopathy

Authors: Weinberg GA, Segel GB, and Andolina JR

Publisher: American Academy of Pediatrics 2023

Avery's Neonatology Board Review (2019)

Chapter: White Blood Cells

Authors: Andolina, JR

Publisher: Elsevier 2019

Avery's Neonatology Board Review (2019)

Chapter: Transfusion Therapy in Neonates

Authors: Andolina, JR

Publisher: Elsevier 2019

Avery's Neonatology Board Review (2019)

Chapter: Solid Tumors and Leukemias

Authors: Andolina, JR

Publisher: Elsevier 2019

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0 stars

During this visit, did this provider show respect for what you had to say?

5.0 stars

During this visit did this provider give you easy to understand information about these health questions or concerns?

5.0 stars

During this visit, did this provider listen carefully to you?

5.0 stars

During this visit, did this provider explain things in a way that was easy to understand?

5.0 stars

Patient Comments

5.0 stars

Most personable & easy to talk to doctor ever.

Jul 26, 2023

5.0 stars

Excellent service! I strongly recommend this care provider.

Jun 11, 2023

5.0 stars

Dr. Andolina is the best provider we have come across.

Jan 06, 2023

5.0 stars

Excellent dr.! Best we have seen!

Feb 22, 2022